Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Blood Glucose Archives
Print | Email | Share | Comments (0)

Protein Targeted to Prevent Kidney Disease


Jan 1, 1997

The Philadelphia-based Exocell, Inc. has recently signed an agreement with Eurand International for the clinical development of an orally administered compound that could help prevent diabetic kidney disease. The compound, EXO-226, will be produced and supplied by Eurand for use in the first phase of clinical trials for FDA approval. Exocell anticipates that these trials will begin in early 1997.

EXO-226 would prevent kidney damage by lowering the levels of glycated albumin in the blood stream. Albumin is a simple protein that is found in many varieties in the tissues and fluids of plants and animals. As R.S. Clements, MD, of Exocell explained to DIABETES HEALTH, the excess sugar in the blood of a person with diabetes binds to this protein and in turn this glycated albumin damages kidney cells and leads to the development of diabetic kidney disease, or nephropathy. EXO-226 works by keeping albumin from becoming glycated. In animal experiments Exocell has been successful in showing that lowering the levels of glycated albumin prevents kidney damage in diabetes.

In the United States, diabetic nephropathy is the cause of 35 percent of the cases of end stage kidney disease and is the largest cause of kidney failure that results in dialysis or transplantation.

Despite the fact that clinical trials have yet to be started, President and Chief Scientific Officer at Exocell, Dr. Margo P. Cohen, comments, "Our agreement with Eurand assures the rapid development of EXO-226 into a product that will protect people with diabetes from one of the most feared complications of the disease."

While Dr. Cohen concedes that the risk of kidney disease can be lowered by normalizing blood glucose levels, she points out that this degree of control is unachievable in most cases of diabetes. With EXO-226, Exocell is attempting to avoid the problem by directly addressing a causal link between high blood sugars and kidney disease.


Categories: Blood Glucose, Blood Sugar, Diabetes, Kidney Care (Nephropathy), Medications Research



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Jan 1, 1997

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.